1. Home
  2. IPHA vs MSGY Comparison

IPHA vs MSGY Comparison

Compare IPHA & MSGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • MSGY
  • Stock Information
  • Founded
  • IPHA 1999
  • MSGY 2018
  • Country
  • IPHA France
  • MSGY Hong Kong
  • Employees
  • IPHA N/A
  • MSGY N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • MSGY
  • Sector
  • IPHA Health Care
  • MSGY
  • Exchange
  • IPHA Nasdaq
  • MSGY Nasdaq
  • Market Cap
  • IPHA 160.1M
  • MSGY 186.3M
  • IPO Year
  • IPHA 2019
  • MSGY 2025
  • Fundamental
  • Price
  • IPHA $2.05
  • MSGY $14.40
  • Analyst Decision
  • IPHA Strong Buy
  • MSGY
  • Analyst Count
  • IPHA 1
  • MSGY 0
  • Target Price
  • IPHA $11.00
  • MSGY N/A
  • AVG Volume (30 Days)
  • IPHA 14.6K
  • MSGY 196.2K
  • Earning Date
  • IPHA 09-17-2025
  • MSGY 01-01-0001
  • Dividend Yield
  • IPHA N/A
  • MSGY N/A
  • EPS Growth
  • IPHA N/A
  • MSGY N/A
  • EPS
  • IPHA N/A
  • MSGY 0.10
  • Revenue
  • IPHA $14,839,695.00
  • MSGY $23,318,482.00
  • Revenue This Year
  • IPHA $350.96
  • MSGY N/A
  • Revenue Next Year
  • IPHA $32.92
  • MSGY N/A
  • P/E Ratio
  • IPHA N/A
  • MSGY $139.53
  • Revenue Growth
  • IPHA N/A
  • MSGY 13.04
  • 52 Week Low
  • IPHA $1.29
  • MSGY $3.83
  • 52 Week High
  • IPHA $3.51
  • MSGY $18.68
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 46.87
  • MSGY N/A
  • Support Level
  • IPHA $1.93
  • MSGY N/A
  • Resistance Level
  • IPHA $2.19
  • MSGY N/A
  • Average True Range (ATR)
  • IPHA 0.11
  • MSGY 0.00
  • MACD
  • IPHA -0.01
  • MSGY 0.00
  • Stochastic Oscillator
  • IPHA 49.66
  • MSGY 0.00

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About MSGY Masonglory Limited Ordinary Shares

Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.

Share on Social Networks: